News Abivax

Equities

ABVX

FR0012333284

Market Closed - Euronext Paris Other stock markets 11:35:02 2024-06-11 am EDT			5-day change	1st Jan Change
13.08 ^EUR	+0.62%		+6.69%	+33.20%

May. 20	BTIG Initiates Abivax at Buy Rating With $43 Price Target	MT
May. 08	Abivax: four abstracts to be presented on obefazimod	CF

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Abivax : Breakdown of the vote by resolution	Jun. 04	PU
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting	Jun. 04	AQ
BTIG Initiates Abivax at Buy Rating With $43 Price Target	May. 20	MT
Abivax: four abstracts to be presented on obefazimod	May. 08	CF
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024	May. 08	EQ
Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024	May. 08	CI
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents	May. 07	EQ
Abivax: share price rises as two analysts express optimism	Apr. 29	CF
Piper Sandler Starts Abivax With Overweight Rating, $42 Price Target	Apr. 29	MT
Guggenheim Starts Abivax With Buy Rating, $50 Price Target	Apr. 29	MT
Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating	Apr. 11	MT
Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024	Apr. 08
Abivax publishes financial reports with the French and U.S. securities regulatory agencies	Apr. 08	AQ
Abivax publishes financial reports with the French and U.S. securities regulatory agencies	Apr. 05	EQ
ABIVAX Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
Abivax reports 2023 financial results and operational update	Apr. 02	EQ
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn's and Colitis Organization (ECCO)	Feb. 14	AQ
Abivax: presentation on obefazimod at the ECCO congress	Feb. 13	CF
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)	Feb. 13	EQ
ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality	Feb. 07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Abivax

Equities

ABVX

FR0012333284

Summary

Filters